Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung CancerSabine Schmid, Geoffrey Liu, Sierra Cheng et al.|Clinical Lung Cancer|2022Cited by 23
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Geoffrey Liu, Sierra Cheng et al.|Lung Cancer|2022Cited by 11
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohortY Q Li, Geoffrey Liu, Michael K. Wong et al.|Lung Cancer|2024Cited by 4
TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancerAmit P. Bhavsar, Asna Latif, Erika N. Scott et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 4
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?Miguel García-Pardo, G. Liu, Sussane Schmid et al.|Journal of Thoracic Oncology|2021Cited by 3